CYTK241220P80000
- 22.45
- 0.000.00%
Cytokinetics Newsroom
RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)
Insider Sale: Director at $CYTK (CYTK) Sells 742 Shares
Calculating The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
Cytokinetics Price Target Raised to $103 From $99 at Mizuho
Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?
Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103
Express News | Cytokinetics Inc : Mizuho Raises Target Price to $103 From $99
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Unusual Options Activity: MET, CNH and Others Attract Market Bets, MET V/OI Ratio Reaches 318.2
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120
Cytokinetics' Hold Rating Amid Bayer Partnership and Acquisition Uncertainty
Cytokinetics Gains 'Buy' Rating Due to Strategic Collaborations and Potential FDA Approval
Cytokinetics Partnership Demonstrates Value of Aficamten, Says JMP Securities
Cytokinetics Secures Strategic Licensing Deal With Bayer, Boosting Global Prospects for Aficamten
Cytokinetics, Bayer Partner to Develop, Commercialize Potential Cardiomyopathy Treatment in Japan
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
Bayer has reached a partnership with cytokinetics (CYTK.US) to develop and commercialize the hypertrophic cardiomyopathy treatment Aficamten in Japan.
Bayer has reached a collaboration agreement with cytokinetics to obtain the exclusive development and commercialization rights for Cytokinetics' hypertrophic cardiomyopathy (HCM) therapy, Aficamten, in japan, but must adhere to certain development rights retained by Cytokinetics.
Express News | Cytokinetics Inc - Bayer to Conduct Phase 3 Trial in Japanese Patients With Obstructive HCM
Express News | Cytokinetics Inc - to Receive €50 Million Upfront, up to €90 Million in Milestones